Amount of funding, not source, has greatest impact on FDA approval time

12/18/2003 | Health Affairs

Researchers who studied the approval times of drug applications since the advent of the Prescription Drug User Fee Act (PDUFA) of 1992, conclude it is the amount of funding FDA receives for staff research rather than the source of the funds that makes the difference in how quickly the agency reviews new drug applications. A study by researchers determined that NDA review times shortened by 3.3 months for every 100 additional FDA staffers and concluded the amount of funding seems to have a more direct influence on review times than the fact the funds come from drugmakers.

View Full Article in:

Health Affairs

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY